Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-777607 in advanced solid tumors
NCT00605618Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BMS-817378 in solid tumor, gastroesophageal junction cancer, prostate cancer (PCa) and 2 more, sponsored by Bristol Myers Squibb. Primary endpoints: Safety and efficacy assessment including vitals signs, physical assessments, and blood tests up to 24 months and Tumor assessments up to 24 months. Started Mar 2008; status: completed.
02
Drugs
BMS-817378
03
Conditions
solid tumorgastroesophageal junction cancerprostate cancer (PCa)head and neck squamous cell carcinoma (HNSCC)papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT00605618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00605618.